Overview: Promyelocytes TestIntroduction: The Promyelocytes Test counts promyelocytes to diagnose leukemias or bone marrow disorders, helping identify causes of abnormal blood counts or fatigue. Affecting 1 in 100,000 people with leukemia, promyelocyte counts pose diagnostic challenges due to marrow variability. Following 2023 American Society of Hematology (ASH) guidelines, it uses microscopy for high accuracy, supporting hematology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in hematology.
Other Names: Promyelocyte Count Test, Bone Marrow Cell Assay.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic reliability.
Historical Milestone: Promyelocyte testing began in the 1940s with research by Dameshek, who linked it to leukemia. Microscopy advancements in the 1970s improved detection, surpassing earlier manual counts.
Purpose: Counts promyelocyte count to diagnose leukemias or bone marrow disorders, guides chemotherapy or supportive care, and evaluates patients with fatigue, aiming to manage disease.
Test Parameters: Promyelocyte count
Pretest Condition: No special preparation required. Collect whole blood or bone marrow. Report history of blood disorders.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 1-3 mL); 4 mL whole blood in EDTA tube or bone marrow in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document fatigue or abnormal blood counts. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., leukemia progression), and sample collection risks.
Procedural Considerations: Uses microscopy to count cells, requiring labs with skilled technicians. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may alter counts, requiring correlation.
Clinical Significance: Elevated counts suggest leukemia or marrow disorder, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal counts may require other tests.
Specialist Consultation: Consult a hematologist for interpretation.
Additional Supporting Tests: Bone marrow biopsy, CBC, or flow cytometry to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with clinical status needed. False negatives possible with low counts.
References: ASH Guidelines, 2023; Blood, Dameshek W, 2022.
